(Q51996299)

19 April 2018

title

Adjuvant synergy: the effects of nasal coadministration of adjuvants. (English)

1 reference

19 April 2018

author

Sterghios A. Moschos

1

1 reference

19 April 2018

author name string

Bramwell VW

2

1 reference

19 April 2018

Somavarapu S

3

1 reference

19 April 2018

Alpar HO

4

1 reference

19 April 2018

publication date

1 December 2004

1 reference

19 April 2018

Immunology & Cell Biology

published in

1 reference

19 April 2018

volume

82

1 reference

19 April 2018

issue

6

1 reference

19 April 2018

page(s)

628-637

1 reference

19 April 2018

Nasal delivery of vaccines

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01280.X

Current status of DNA vaccines and their route of administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01280.X

Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01280.X

MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01280.X

Mucosal HIV vaccines: where are we now?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01280.X

Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01280.X

Negligible adjuvant effect for antibody responses and frequent adverse events associated with IL-12 treatment in humans vaccinated with pneumococcal polysaccharide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01280.X

Delivery of IL-12 intranasally leads to reduced IL-12-mediated toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01280.X

The concomitant use of the LTK63 mucosal adjuvant and of chitosan-based delivery system enhances the immunogenicity and efficacy of intranasally administered vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01280.X

Enhancement of paracellular drug transport with highly quaternized N-trimethyl chitosan chloride in neutral environments: in vitro evaluation in intestinal epithelial cells (Caco-2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01280.X

Effects of N-trimethyl chitosan chloride, a novel absorption enhancer, on caco-2 intestinal epithelia and the ciliary beat frequency of chicken embryo trachea

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01280.X

Transport of nanoparticles across the rat nasal mucosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01280.X

Absorption Enhancers for Nasal Drug Delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01280.X

Changes in cisplatin delivery due to surface-coated poly (lactic acid)-poly(epsilon-caprolactone) microspheres

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01280.X

Growth factor releasing porous poly (epsilon-caprolactone)-chitosan matrices for enhanced bone regenerative therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01280.X

Local and systemic immune response to a microencapsulated sub-unit vaccine for plague

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01280.X

Nasal drug delivery--possibilities, problems and solutions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01280.X

Protective levels of diphtheria-neutralizing antibody induced in healthy volunteers by unilateral priming-boosting intranasal immunization associated with restricted ipsilateral mucosal secretory immunoglobulin a

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01280.X

Chitosan as a novel nasal delivery system for vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01280.X

A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM(197)) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01280.X

Parenteral adjuvant activities of Escherichia coli heat-labile toxin and its B subunit for immunization of mice against gastric Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01280.X

Mucosal immunization against hepatitis B virus by intranasal co-administration of recombinant hepatitis B surface antigen and recombinant cholera toxin B subunit as an adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01280.X

Mucosal immunization with DNA vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01280.X

Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01280.X

Intranasal immunotherapy for the treatment of Alzheimer's disease: Escherichia coli LT and LT(R192G) as mucosal adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01280.X

A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01280.X

Modulation of dendritic cell endocytosis and antigen processing pathways by Escherichia coli heat-labile enterotoxin and mutant derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01280.X

Effects of the adjuvant cholera toxin on dendritic cells: stimulatory and inhibitory signals that result in the amplification of immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01280.X

Cholera toxin suppresses interleukin (IL)-12 production and IL-12 receptor beta1 and beta2 chain expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01280.X

Safety and efficacy of low dose Escherichia coli enterotoxin adjuvant for urease based oral immunisation against Helicobacter pylori in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01280.X

Penetration of protein toxins into cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01280.X

The B subunit of Escherichia coli heat labile enterotoxin abrogates oral tolerance, promoting predominantly Th2‐type immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01280.X

Intranasal vaccination against plague, tetanus and diphtheria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01280.X

Protection of BALB/c mice against experimental Helicobacter pylori infection by oral immunisation with H pylori heparan sulphate-binding proteins coupled to cholera toxin beta-subunit

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01280.X

Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01280.X

Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01280.X

Recent advances in mucosal vaccines and adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01280.X

An enzymatically active a domain is required for cholera-like enterotoxins to induce a long-lived blockade on the induction of oral tolerance: new method for screening mucosal adjuvants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01280.X

Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01280.X

Effect of MDP-Lys(L18) as a mucosal immunoadjuvant on protection of mucosal infections by Sendai virus and rotavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01280.X

Squalene and squalane emulsions as adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01280.X

Adamantylamide dipeptide as effective immunoadjuvant in rabbits and mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01280.X

Adjuvant activity of muramyl dipeptide derivatives to enhance immunogenicity of a hantavirus-inactivated vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01280.X

Upregulation of costimulatory molecules induced by lipopolysaccharide and double-stranded RNA occurs by Trif-dependent and Trif-independent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01280.X

Dendritic-cell function in Toll-like receptor- and MyD88-knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01280.X

NODs: intracellular proteins involved in inflammation and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01280.X

Enhancing activity of mycobacterial cell-derived adjuvants on immunogenicity of recombinant human hepatitis B virus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01280.X

Controlled delivery of antigens and adjuvants in vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01280.X

Interleukins and IgA synthesis. Human and murine interleukin 6 induce high rate IgA secretion in IgA-committed B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01280.X

The role of interleukin-6 in mucosal IgA antibody responses in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01280.X

Cytokines induce the development of functionally heterogeneous T helper cell subsets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01280.X

Vaccine-induced reduction of Helicobacter pylori colonization in mice is interleukin-12 dependent but gamma interferon and inducible nitric oxide synthase independent

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01280.X

Protection against Helicobacter pylori infection following immunization is IL-12-dependent and mediated by Th1 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01280.X

ISCOMs and other saponin based adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01280.X

CpG ODN 2006 and IL-12 are comparable for priming Th1 lymphocyte and IgG responses in cattle immunized with a rickettsial outer membrane protein in alum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01280.X

10.1111/J.0818-9641.2004.01280.X

21 January 2018

Identifiers

DOI

1 reference

19 April 2018

1 reference

19 April 2018